Nutri-Pharmaceuticals Research, Inc. (Pink Sheets:�NRPR) is pleased to report that its unaudited Pro Forma Results for 2006 show increased revenues by 84% in fiscal 2006 and it has a new backlog of orders which could increase sales by almost double again in fiscal 2007. Copies of the unaudited financials are available upon request and the audit is scheduled to start on May 15. The company had extraordinary one-time expenses due to moving plant and equipment to a new, much larger 30,000 sq ft building and one-time stock and stock option expenses to employees. Nutri-Pharmaceuticals has proprietary research and technology for converting oils to powders without altering the molecular structure and are beginning to produce meaningful revenue with significant contracts not only in the U.S., but also throughout Europe and Asia as significant long-term contracts have been secured which should enhance revenues dramatically this year. Statements in this press release other than statements of historical fact are forward looking statements. Although management believes statements are reasonable it can give no assurance that such expectations will be achieved.
Nutri Pharmaceuticals Re... (PK) (USOTC:NRPR)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos Nutri Pharmaceuticals Re... (PK).
Nutri Pharmaceuticals Re... (PK) (USOTC:NRPR)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos Nutri Pharmaceuticals Re... (PK).